News and Announcements
The Investor Turn-Off: Avoid This Common Blunder in Your Pitch
- Published September 19, 2023 11:00PM UTC
- Publisher Wholesale Investor
- Categories Capital Raising Tips
Every founder dreams of securing that game-changing investment to propel their startup to new heights. However, in the quest to impress investors, many unknowingly commit a cardinal sin that can instantly dampen investor interest.
In this video, Steve Torso sheds light on a prevalent and frustrating habit that founders often fall prey to: comparing their startups to industry giants like Airbnb, Uber, or Facebook. While the intention might be to convey potential and ambition, this approach can backfire spectacularly.
Why Comparisons Don’t Work:
- Irrelevance: Drawing parallels to multi-billion-dollar businesses can come across as irrelevant, especially if your business model or industry doesn’t align with the giants you’re referencing.
- Lack of Originality: Investors are on the lookout for unique and innovative solutions. By likening your startup to well-established companies, you risk appearing unoriginal or even lazy in your pitch.
- Miscommunication: The goal is to articulate your business model and value proposition clearly. Using comparisons can muddle your message and leave investors confused about what you truly offer.
Crafting a Compelling Pitch: Instead of leaning on comparisons, focus on your unique selling proposition (USP). What sets your startup apart? Why should investors be excited about your venture? By honing in on your USP and communicating it effectively, you stand a better chance of capturing an investor’s attention and, more importantly, their trust.
In conclusion, while the allure of drawing parallels to industry giants can be tempting, it’s essential to remember that investors are looking for the next big thing, not a replica of what already exists.
Capital Raising Tips
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
